Εμφάνιση απλής εγγραφής

dc.creatorThomas K., Lazarini A., Kaltsonoudis E., Drosos A., Papalopoulos I., Sidiropoulos P., Tsatsani P., Gazi S., Pantazi L., Boki K.A., Katsimbri P., Boumpas D., Fragkiadaki K., Tektonidou M., Sfikakis P.P., Karagianni K., Sakkas L.I., Grika E.P., Vlachoyiannopoulos P.G., Evangelatos G., Iliopoulos A., Dimitroulas T., Garyfallos A., Melissaropoulos K., Georgiou P., Areti M., Georganas C., Vounotrypidis P., Kitas G.D., Vassilopoulos D.en
dc.date.accessioned2023-01-31T10:08:27Z
dc.date.available2023-01-31T10:08:27Z
dc.date.issued2020
dc.identifier10.1177/1759720X20937132
dc.identifier.issn1759720X
dc.identifier.urihttp://hdl.handle.net/11615/79706
dc.description.abstractBackground: Data regarding the real-life predictors of low disease activity (LDA) in rheumatoid arthritis (RA) patients are limited. Our aim was to evaluate the rate and predictors of LDA and treatment patterns in RA. Methods: This was a multicenter, prospective, RA cohort study where patients were evaluated in two different time points approximately 12 months apart. Statistical analysis was performed in order to identify predictors of LDA while patterns of disease-modifying anti-rheumatic drug [DMARDs; conventional synthetic (csDMARD) or biologic (bDMARD)] and glucocorticoid (GC) use were also recorded. Results: The total number of patients included was 1317 (79% females, mean age: 62.9 years, mean disease duration: 10.3 years). After 1 year, 57% had achieved LDA (DAS28ESR<3.2) while 43% did not (34%: moderate disease activity: DAS28ESR ⩾3.2 to <5.1, 9%: high disease activity, DAS28ESR ⩾5.1). By multivariate analysis, male sex was positively associated with LDA [odds ratio (OR) = 2.29 p < 0.001] whereas advanced age (OR = 0.98, p = 0.005), high Health Assessment Questionnaire (HAQ) score (OR = 0.57, p < 0.001), use of GCs (OR = 0.75, p = 0.037) or ⩾2 bDMARDs (OR = 0.61, p = 0.002), high co-morbidity index (OR = 0.86, p = 0.011) and obesity (OR = 0.62, p = 0.002) were negative predictors of LDA. During follow-up, among active patients (DAS28ESR >3.2), 21% initiated (among csDMARDs users) and 22% switched (among bDMARDs users) their bDMARDs. Conclusion: In a real-life RA cohort, during 1 year of follow-up, 43% of patients do not reach treatment targets while only ~20% of those with active RA started or switched their bDMARDs. Male sex, younger age, lower HAQ, body mass index and co-morbidity index were independent factors associated with LDA while use of GCs or ⩾2 bDMARDs were negative predictors. © The Author(s), 2020.en
dc.language.isoenen
dc.sourceTherapeutic Advances in Musculoskeletal Diseaseen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85091714492&doi=10.1177%2f1759720X20937132&partnerID=40&md5=285002c1d79dcb7e502979bf0c6b2b6d
dc.subjectcyclic citrullinated peptide antibodyen
dc.subjectdisease modifying antirheumatic drugen
dc.subjectglucocorticoiden
dc.subjectnonsteroid antiinflammatory agenten
dc.subjectrheumatoid factoren
dc.subjectadulten
dc.subjectarthroplastyen
dc.subjectArticleen
dc.subjectbody massen
dc.subjectclinical outcomeen
dc.subjectcohort analysisen
dc.subjectcomorbidity assessmenten
dc.subjectDAS28en
dc.subjectdisease activityen
dc.subjectdyslipidemiaen
dc.subjecterythrocyte sedimentation rateen
dc.subjectfemaleen
dc.subjectHealth Assessment Questionnaireen
dc.subjecthumanen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmiddle ageden
dc.subjectmulticenter studyen
dc.subjectobesityen
dc.subjectosteoporosisen
dc.subjectpriority journalen
dc.subjectprospective studyen
dc.subjectrheumatoid arthritisen
dc.subjectSAGE Publications Ltden
dc.titleTreatment patterns and achievement of the treat-to-target goals in a real-life rheumatoid arthritis patient cohort: data from 1317 patientsen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής